Biogen 232SM303
Brief description of study
This study will evaluate HD nusinersen in participants previously treated with risdiplam who may not be receiving the optimal benefit from treatment because they have reached the dose ceiling of 5 mg.This Phase 3b, open-label, single-arm, interventional study will evaluate the efficacy and safety of HD nusinersen in nonambulatory participants with later-onset SMA (symptom onset at age 6 months) who received treatment with risdiplam in the clinical practice setting.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
